ApoG2 as the most potent gossypol derivatives inhibits cell growth and induces apoptosis on gastric cancer cells

Biomedicine and Pharmacotherapy

Volumn 67, Issue 1, 2013, Pages 88-95

  Xin, J ^a   Zhan, Y H ^a   Xia, L M ^c   Zhu, H W ^c,d   Nie, Y Z ^c   Liang, J M ^a   Tian, J ^a,b  

^a XIDIAN UNIVERSITY   (China)

^b INSTITUTE OF AUTOMATION   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

ApoG2; Gastric cancer; Small molecule inhibitor

Indexed keywords

CASPASE 3; GOSSYPOL; PROTEIN; PROTEIN APOG2; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH CARCINOMA; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GOSSYPOL; HUMANS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TIME FACTORS; UP-REGULATION;

EID: 84873092081     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.10.016     Document Type: Article

References (41)

1. Parkin D.M. International variation. Oncogene 2004, 23:6329-6340.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Morse M.A., Stoner G.D. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993, 14:1737-1746.
4. Macdonald J.S. Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 2004, 54(Suppl. 1):S4-S11.
5. Zhang D., Fan D. Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther 2007, 7:1369-1378.
6. Debatin K.M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004, 53:153-159.
7. Jendrossek V. The intrinsic apoptosis pathways as a target in anticancer therapy. Curr Pharm Biotechnol 2012, 13:1426-1438.
8. Krajewska M., Fenoglio-Preiser C.M., Krajewski S., Song K., Macdonald J.S., Stemmerman G., et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996, 149:1449-1457.
9. Reed J.C., Zha H., Aime-Sempe C., Takayama S., Wang H.G. Structure-function analysis of Bcl-2 family proteins: regulators of programmed cell death. Adv Exp Med Biol 1996, 406:99-112.
10. Petros A.M., Olejniczak E.T., Fesik S.W. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004, 1644:83-94.
11. Marzo I., Naval J. Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol 2008, 76:939-946.
12. Huang Z. Small molecule inhibitors of Bcl-2 function: modulators of apoptosis and promising anticancer agents. Curr Opin Drug Discov Devel 2000, 3:565-574.
13. Wang S., Yang D., Lippman M.E. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003, 30(Suppl. 16):133-142.
14. Al-Katib A.M., Sun Y., Goustin A.S., Azmi A.S., Chen B., Aboukameel A., et al. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. J Hematol Oncol 2009, 2:8.
15. Azmi A.S., Mohammad R.M. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 2009, 218:13-21.
16. Bodur C., Basaga H. Bcl-2 Inhibitors: emerging drugs in cancer therapy. Curr Med Chem 2012, 19:1804-1820.
17. Coutinho E.M. Gossypol: a contraceptive for men. Contraception 2002, 65:259-263.
18. Naik H., Petrylak D., Yagoda A., Lehr J., Akhtar A., Pienta K. Preclinical studies of gossypol in prostate carcinoma. Int J Oncol 1995, 6:209-213.
19. Gilbert N.E., O'Reilly J.E., Chang C.J., Lin Y.C., Brueggemeier R.W. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci 1995, 57:61-67.
20. Bushunow P., Reidenberg M.M., Wasenko J., Winfield J., Lorenzo B., Lemke S., et al. Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 1999, 43:79-86.
21. Meng Y., Tang W., Dai Y., Wu X., Liu M., Ji Q., et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008, 7:2192-2202.
22. Balakrishnan K., Wierda W.G., Keating M.J., Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008, 112:1971-1980.
23. Gunassekaran G.R., Priya D.K., Gayathri R., Sakthisekaran D. In vitro and in vivo studies on antitumor effects of gossypol on human stomach adenocarcinoma (AGS) cell line and MNNG induced experimental gastric cancer. Biochem Biophys Res Commun 2011, 411:661-666.
24. Jiang J., Slivova V., Jedinak A., Sliva D. Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-kappaB/AP-1 dependent- and independent-signaling. Clin Exp Metastasis 2012, 29:165-178.
25. Baggstrom M.Q., Qi Y., Koczywas M., Argiris A., Johnson E.A., Millward M.J., et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 2011, 6:1757-1760.
26. Stein R.C., Joseph A.E., Matlin S.A., Cunningham D.C., Ford H.T., Coombes R.C. A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 1992, 30:480-482.
27. Hu Z.Y., Zhu X.F., Zhong Z.D., Sun J., Wang J., Yang D., et al. ApoG2, a novel inhibitor of anti-apoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer 2008, 123:2418-2429.
28. Hu Z.Y., Sun J., Zhu X.F., Yang D., Zeng Y.X. ApoG2 induces cell cycle arrest of nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. J Transl Med 2009, 7:74.
29. Zhang X.Q., Huang X.F., Hu X.B., Zhan Y.H., An Q.X., Yang S.M., et al. Apogossypolone, a novel inhibitor of anti-apoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro. Asian J Androl 2010, 12:697-708.
30. Sun Y., Wu J., Aboukameel A., Banerjee S., Arnold A.A., Chen J., et al. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biol Ther 2008, 7:1418-1426.
31. Sun J., Li Z.M., Hu Z.Y., Zeng Z.L., Yang D.J., Jiang W.Q. Apogossypolone inhibits cell growth by inducing cell cycle arrest in U937 cells. Oncol Rep 2009, 22:193-198.
32. Wei J., Kitada S., Stebbins J.L., Placzek W., Zhai D., Wu B., et al. Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of anti-apoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2010, 53:8000-8011.
33. Sun J., Li Z.M., Hu Z.Y., Lin X.B., Zhou N.N., Xian L.J., et al. ApoG2 inhibits anti-apoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells. Anticancer Drugs 2008, 19:967-974.
34. Arnold A.A., Aboukameel A., Chen J., Yang D., Wang S., Al-Katib A., et al. Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model. Mol Cancer 2008, 7:20.
35. Banerjee S., Choi M., Aboukameel A., Wang Z., Mohammad M., Chen J., et al. Preclinical studies of apogossypolone, a novel pan inhibitor of Bcl-2 and Mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. Pancreas 2010, 39:323-331.
36. Mi J.X., Wang G.F., Wang H.B., Sun X.Q., Ni X.Y., Zhang X.W., et al. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma. Acta Pharmacol Sin 2008, 29:1467-1477.
37. Hu M., Xu L., Yin L., Qi Y., Li H., Xu Y., et al. Cytotoxicity of dioscin in human gastric carcinoma cells through death receptor and mitochondrial pathways. J Appl Toxicol 2012, 10.1002/jat.2715.
38. Zhan Y.H., Jia G.F. A novel synthesis method of apogossypolone and its antitumor activity. Lett Drug Des Disc 2009, 6:129-132.
39. Zhan Y.H., Jia G.F., Wu D.C., Xu Y.Q., Xu L. Design and synthesis of a gossypol derivative with improved antitumor activities. Archiv der Pharmazie 2009, 342:223-229.
40. Lehr H.A., Mankoff D.A., Corwin D., Santeusanio G., Gown A.M. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997, 45:1559-1565.
41. Scopa C.D., Vagianos C., Kardamakis D., Kourelis T.G., Kalofonos H.P., Tsamandas A.C. Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 2001, 9:329-334.